Academic Highlights summarize faculty presentations from symposia, roundtable meetings, and teleconferences. They include case-based questions that help learners pause for reflection on key clinical messages. Many are CME accredited.
What are some of the challenges you face in overcoming adherence issues and providing patient-centered care for people living with schizophrenia? Drs Harvey and Kane offer evidence and clinical experience on these topics in this journal CME activity.
In this article focusing on maintenance treatment of bipolar I disorder, experts discuss functional impairment, the potential for LAI antipsychotics to address nonadherence, and the characteristics of patients who may be helped by LAI antipsychotic treatment.
In this journal CME activity, find experts' recommendations for reducing schizophrenia relapse, such as adopting a patient-centered approach, selecting medications based on current evidence, and implementing psychosocial interventions.
Review highlights from 2 experts' presentations on identifying and treating tardive dyskinesia. Quotes from actual patients illustrate the embarrassment that they feel and show why even mild movements should be treated if patients are distressed by them.
Learn from experts in neurology, psychiatry, neuropsychology, and primary care about working with patients and care partners to create management plans for Alzheimer's disease that ensure safety, optimize patient autonomy, and minimize agitation and conflict.
Long-acting injectable antipsychotics can be a powerful strategy in helping patients to receive ongoing benefit from treatment. You might think that you have adequately explained this treatment option to patients, but they may not have understood. How can communication be improved? See this Academic Highlights to find out.
Given the similarity in clinical presentation between major depressive disorder (MDD) and the depressive episodes of bipolar disorder (BP), misdiagnoses occur too often. Read this Academic Highlights to learn to make an accurate differential diagnosis between MDD and BP while recognizing complexities related to not only psychiatric and medical comorbidities but also the evolving presentation of symptoms as the disorders progress.
Some antipsychotics used to treat MDD are associated with activating or sedating effects. In this Academic Highlights, 4 experts offer clinical insights into the impact of these effects on treatment adherence, patient functioning, and quality of life.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”